磷酸奥司他韦胶囊治疗慢性阻塞性肺疾病合并流感样症状患者的疗效观察

Curative effect observation of Oseitamivir Phosphate Capsules on chronic obstructive pulmonary diseasecombined with flu-like symptoms

目的评价磷酸奥司他韦胶囊治疗慢性阻塞性肺疾病（COPD）合并流感样症状患者的疗效及安全性。方法选取2017年1月至2017年12月就诊于我科的COPD合并流感样症状患者100例。随机分为实验组50例，对照组50例}2组均给予常规对症治疗，对照组给予四季抗病毒合剂口服，实验组给予磷酸奥司他韦胶囊口服治疗，对比2组的总有效率，临床症状缓解时间及不良反应，同时对比2组患者的治疗费用及治疗前后的肺功能变化情况。结果实验组总有效率明显高于对照组（χ2=6．349，P〈0．05）；2组退热起效时间相当，差异无统计学意义（t=0．539，P〉0．05）；实验组完全退热时间、肌肉酸痛缓解时间、疲劳缓解时间、住院时间均更短于对照组；2组均出现较轻不良反应，经对症处理后症状消失，2组对比差异无统计学意义（χ20．078，P〉0．05）。2组患者治疗费用差异无统计学意义（t=1．492，P〉O．05），治疗后肺功能均有所改善，组间对比无明显差异。结论COPD合并流感样症状患者早期使用磷酸奥司他韦胶囊治疗，疗效显著，安全性及耐受性较高，未增加患者经济负担，值得临床推广。

Objective To evaluate efficacy and safety of Oseltamivir Phosphate Capsules in treating patients with chronic obstructive pulmonary diseases （COPD） combined with flu-like symptoms. Methods One hundred patients with COPD combined influenza-like symptoms who received treatment in our department from January 2017 to December 2017 were chosen. These patients were randomly divided into experimental group and control group with 50 in each group respectively. Conventional targeted therapy was offered to two groups. Oral Siji antivirus mixture was administered to control group and Oseltamivir Phosphate Capsules were offered to experimental group. Total effective rate, response time of clinical symptoms and adverse effects in the two group were compared. Meanwhile, treatment cost and pulmonary function changes of patients in the two groups were analyzed. Results Total effective rate in experimental group was obviously higher than that in control group （ χ2 = 6. 349, P = 0. 014）. Onset time of antifebrile in the two groups was equivalent and there was no significant difference （ t =0. 539, P =0. 591）. Onset time of total antifebrile, response time of muscular soreness, response time of fatigue and hospital stay in experimental group were much shorter than that in control group. Mild adverse effects were seen in two groups and the symptoms disappeared after expectant treatment. Comparison＇of two groups indicated no great difference （ Z2 =0. 078, P =0. 779）. There was no obvious difference regarding treatment cost for patients in the two groups （ t = 1. 492, P =0. 139）. After treatment, pulmonary functions were improved and there was no evident difference in terms of comparison between groups. Conclusions Application of oseltamivir phosphate capsules for early stage treatment of patients with COPD combined influenza-likesymptoms demonstrated significant efficacy. The safety and tolerance were quite higher and the patients suffered from no increased economic burdens, making the treatment scheme worthy of clinical application.